(919) 237-4897 info@t3dtherapeutics.com

Our Mission

A Transformational Approach to Treating Alzheimer’s Disease … and more.

T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, as a potential ‘First-in-Class’ and ‘Best-in-Class’ disease-modifying, breakthrough medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease.

T3D-959 is designed as an orally-delivered, once-a-day medicine for Alzheimer’s disease patients with mild to moderate disease severity, and potentially also for patients with mild cognitive impairment (MCI). In addition, T3D believes that the mechanism of action of T3D-959, which is designed to provide anti-inflammatory and anti-wasting effects, along with the ability to repair damaged nerve cells, may provide therapeutic benefit in other central nervous system (CNS) or neurodegenerative disorders.